Terms: = Germ cell tumor AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
182 results:
1. CD133 significance in glioblastoma development: in silico and in vitro study.
Abdoli Shadbad M; Nejadi Orang F; Baradaran B
Eur J Med Res; 2024 Mar; 29(1):154. PubMed ID: 38448914
[TBL] [Abstract] [Full Text] [Related]
2. KRAS is a molecular determinant of platinum responsiveness in glioblastoma.
Zuchegna C; Leone S; Romano A; Porcellini A; Messina S
BMC Cancer; 2024 Jan; 24(1):77. PubMed ID: 38225605
[TBL] [Abstract] [Full Text] [Related]
3. Network pharmacology-based strategy to investigate the effect and mechanism of α-solanine against glioma.
Wang C; Liu X; Guo S
BMC Complement Med Ther; 2023 Oct; 23(1):371. PubMed ID: 37865727
[TBL] [Abstract] [Full Text] [Related]
4. FBXO7 Confers Mesenchymal Properties and Chemoresistance in Glioblastoma by Controlling Rbfox2-Mediated Alternative Splicing.
Li S; Chen Y; Xie Y; Zhan H; Zeng Y; Zeng K; Wang L; Zhan Z; Li C; Zhao L; Chen X; Tan Y; Wang Z; Bu J; Song Y; Deng F; Zhou A
Adv Sci (Weinh); 2023 Nov; 10(33):e2303561. PubMed ID: 37822160
[TBL] [Abstract] [Full Text] [Related]
5. Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models.
Dyshlovoy SA; Hauschild J; Venz S; Krisp C; Kolbe K; Zapf S; Heinemann S; Fita KD; Shubina LK; Makarieva TN; Guzii AG; Rohlfing T; Kaune M; Busenbender T; Mair T; Moritz M; Poverennaya EV; Schlüter H; Serdyuk V; Stonik VA; Dierlamm J; Bokemeyer C; Mohme M; Westphal M; Lamszus K; von Amsberg G; Maire CL
Mol Pharm; 2023 Oct; 20(10):4994-5005. PubMed ID: 37733943
[TBL] [Abstract] [Full Text] [Related]
6. treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
Augustyn K; Joseph J; Patel AB; Razmandi A; Ali AN; Tawbi HA
Melanoma Res; 2023 Oct; 33(5):406-416. PubMed ID: 37534686
[TBL] [Abstract] [Full Text] [Related]
7. Protein phosphatase 6 regulates trametinib sensitivity, a mitogen-activated protein kinase kinase (MEK) inhibitor, by regulating mek1/2-ERK1/2 signaling in canine melanoma cells.
Yamamoto M; Fujiwara N
J Vet Med Sci; 2023 Sep; 85(9):977-984. PubMed ID: 37495516
[TBL] [Abstract] [Full Text] [Related]
8. Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response.
Randic T; Magni S; Philippidou D; Margue C; Grzyb K; Preis JR; Wroblewska JP; Nazarov PV; Mittelbronn M; Frauenknecht KBM; Skupin A; Kreis S
Cell Rep; 2023 Jul; 42(7):112696. PubMed ID: 37379213
[TBL] [Abstract] [Full Text] [Related]
9. Trametinib in Patients With
Wisinski KB; Flamand Y; Wilson MA; Luke JJ; Tawbi HA; Hong F; Mitchell EP; Zwiebel JA; Chen H; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Behrens RJ; Pennington KP; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2023 Apr; 7():e2200421. PubMed ID: 37053535
[TBL] [Abstract] [Full Text] [Related]
10. Optically activated mek1/2 inhibitors (Opti-MEKi) as potential antimelanoma agents.
Hao C; Li X; Wang Z; Liu L; He F; Pan Z
Eur J Med Chem; 2023 May; 251():115236. PubMed ID: 36924668
[TBL] [Abstract] [Full Text] [Related]
11. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and mek1/2.
Wang P; Jia X; Lu B; Huang H; Liu J; Liu X; Wu Q; Hu Y; Li P; Wei H; Liu T; Zhao D; Zhang L; Tian X; Jiang Y; Qiao Y; Nie W; Ma X; Bai R; Peng C; Dong Z; Liu K
Signal Transduct Target Ther; 2023 Mar; 8(1):96. PubMed ID: 36872366
[TBL] [Abstract] [Full Text] [Related]
12. High-Throughput Functional Evaluation of map2k1 Variants in Cancer.
Mizuno S; Ikegami M; Koyama T; Sunami K; Ogata D; Kage H; Yanagaki M; Ikeuchi H; Ueno T; Tanikawa M; Oda K; Osuga Y; Mano H; Kohsaka S
Mol Cancer Ther; 2023 Feb; 22(2):227-239. PubMed ID: 36442478
[TBL] [Abstract] [Full Text] [Related]
13. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With
Klute KA; Rothe M; Garrett-Mayer E; Mangat PK; Nazemzadeh R; Yost KJ; Duvivier HL; Ahn ER; Cannon TL; Alese OB; Krauss JC; Thota R; Calfa CJ; Denlinger CS; O'Lone R; Halabi S; Grantham GN; Schilsky RL
JCO Precis Oncol; 2022 Nov; 6():e2200191. PubMed ID: 36409971
[TBL] [Abstract] [Full Text] [Related]
14. A first-in-human, phase 1a dose-escalation study of the selective mek1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma.
Mao L; Guo J; Zhu L; Jiang Y; Yan W; Zhang J; Hui AM; Yang Y; Diao L; Tan Y; Zhao H; Jiang Y; Wu Z; Si L
Eur J Cancer; 2022 Nov; 175():125-135. PubMed ID: 36113242
[TBL] [Abstract] [Full Text] [Related]
15. Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors.
Lebedev TD; Khabusheva ER; Mareeva SR; Ivanenko KA; Morozov AV; Spirin PV; Rubtsov PM; Snezhkina AV; Kudryavtseva AV; Sorokin MI; Buzdin AA; Prassolov VS
J Biol Chem; 2022 Aug; 298(8):102226. PubMed ID: 35787369
[TBL] [Abstract] [Full Text] [Related]
16. Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study.
Trippett T; Toledano H; Campbell Hewson Q; Verschuur A; Langevin AM; Aerts I; Howell L; Gallego S; Rossig C; Smith A; Patel D; Pereira LR; Cheeti S; Musib L; Hutchinson KE; Devlin C; Bernardi R; Geoerger B
Target Oncol; 2022 May; 17(3):283-293. PubMed ID: 35715627
[TBL] [Abstract] [Full Text] [Related]
17. A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of mek1/2 Inhibitors in NRAS Mutant Melanoma.
Cai W; Nguyen MQ; Wilski NA; Purwin TJ; Vernon M; Tiago M; Aplin AE
Cancer Res; 2022 Jul; 82(14):2625-2639. PubMed ID: 35657206
[TBL] [Abstract] [Full Text] [Related]
18. Intermittent treatment of BRAF
Kavran AJ; Stuart SA; Hayashi KR; Basken JM; Brandhuber BJ; Ahn NG
Proc Natl Acad Sci U S A; 2022 Mar; 119(12):e2113535119. PubMed ID: 35290123
[TBL] [Abstract] [Full Text] [Related]
19. The Predictive Value of
Ye T; Zhang JY; Liu XY; Zhou YH; Yuan SY; Yang MM; Xie WZ; Gao C; Chen YX; Huang ML; Ye CZ; Chen J
Front Immunol; 2021; 12():785526. PubMed ID: 35069558
[TBL] [Abstract] [Full Text] [Related]
20. FGFR2 loss sensitizes MYCN-amplified neuroblastoma CHP134 cells to CHK1 inhibitor-induced apoptosis.
Ando K; Ohira M; Takada I; Cázares-Ordoñez V; Suenaga Y; Nagase H; Kobayashi S; Koshinaga T; Kamijo T; Makishima M; Wada S
Cancer Sci; 2022 Feb; 113(2):587-596. PubMed ID: 34807483
[TBL] [Abstract] [Full Text] [Related]
[Next]
